2021
Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection
Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.Peer-Reviewed Original ResearchConceptsSevere SARS-CoV-2 infectionSARS-CoV-2 infectionIntensive care unitComplement activationRespiratory failureEndothelial injuryCOVID-19Non-COVID cohortPersonalized clinical trialsAcute respiratory failureInvasive mechanical ventilationSevere COVID-19Tertiary care centerAlternative complement pathwayICU admissionCritical illnessCare unitMechanical ventilationRisk prognosticationWashington University SchoolWorse outcomesCare centerClinical trialsHigh riskPatients
2013
Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia
Siddon AJ, Rinder HM. Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia. American Journal Of Clinical Pathology 2013, 139: 708-712. PMID: 23690112, DOI: 10.1309/ajcplir4gzwx3xka.Peer-Reviewed Original ResearchMeSH KeywordsADP-ribosyl Cyclase 1Beta 2-MicroglobulinFlow CytometryGene Rearrangement, B-LymphocyteHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIncidental FindingsLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisMaleMiddle AgedMutationPrognosisWatchful WaitingZAP-70 Protein-Tyrosine KinaseConceptsChronic lymphocytic leukemiaEarly-stage chronic lymphocytic leukemiaStage chronic lymphocytic leukemiaDisease progressionLymphocytic leukemiaImmunoglobulin heavy chain variable (IGHV) gene mutational statusMonoclonal B-cell lymphoproliferative disorderLaboratory evaluationOvert chronic lymphocytic leukemiaMonoclonal B-cell lymphocytosisB-cell lymphoproliferative disordersAggressive disease progressionSignificant disease progressionIndolent clinical courseSerum β2-microglobulinRoutine laboratory evaluationB-cell lymphocytosisZAP-70 expressionGene mutational statusMonoclonal lymphocytosisClinical courseExpectant observationLymphoproliferative disordersTherapeutic optionsPrognostic marker
2012
Normalized CCND1 expression has prognostic value in mantle cell lymphoma
Siddon AJ, Torres R, Rinder HM, Smith BR, Howe JG, Tormey CA. Normalized CCND1 expression has prognostic value in mantle cell lymphoma. British Journal Of Haematology 2012, 158: 551-553. PMID: 22671703, DOI: 10.1111/j.1365-2141.2012.09181.x.Peer-Reviewed Original Research
2001
The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress
Griffin M, Rinder H, Smith B, Tracey J, Kriz N, Li C, Rinder C. The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress. Anesthesia & Analgesia 2001, 93: 20-27. PMID: 11429331, DOI: 10.1097/00000539-200107000-00005.Peer-Reviewed Original ResearchConceptsCollagen-induced thrombus formationPlatelet hemostasis timePartial thromboplastin timeAntiplatelet effectProthrombin timeAntithrombin effectPlatelet activationProtamine reversalPlatelet functionDirect antiplatelet effectCollagen-dependent platelet activationDirect thrombin inhibitorL-arginyl-chloromethyl ketoneClot Signature AnalyzerEffect of heparinCollagen-induced platelet activationEffect of protamineArterial shear stressBlood lossCardiopulmonary bypassPlatelet dysfunctionProtamine ratioPlatelet aggregometryAnticoagulant effectThromboplastin time
2000
Cocaine, HIV, and their cardiovascular effects: is there a role for ACE-inhibitor therapy?
Margolin A, Avants S, Setaro J, Rinder H, Grupp L. Cocaine, HIV, and their cardiovascular effects: is there a role for ACE-inhibitor therapy? Drug And Alcohol Dependence 2000, 61: 35-45. PMID: 11064182, DOI: 10.1016/s0376-8716(00)00124-1.Peer-Reviewed Original ResearchConceptsACE inhibitor therapyCocaine abuseCocaine useAngiotensin converting enzyme (ACE) inhibitorsDiastolic heart functionNew pharmacologic approachesLevels of dopamineConverting Enzyme InhibitorsCocaine-abusing populationCocaine-abusing patientsConsiderable clinical utilityClass of agentsPlatelet activation studiesCardiovascular sequelaeHIV patientsCardiovascular effectsHIV diseaseHIV-positiveACE inhibitorsHIV serostatusRisk factorsPharmacologic approachesPlatelet abnormalitiesClinical utilityHeart function
1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashion
1998
Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis
Rinder H, Schuster J, Rinder C, Wang C, Schweidler H, Smith B. Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis. Blood 1998, 91: 1288-1294. PMID: 9454759, DOI: 10.1182/blood.v91.4.1288.Peer-Reviewed Original ResearchConceptsRP countsNormal platelet countPlatelet countThrombocytosis patientsPlatelet turnoverHealthy controlsART patientsTreatment responsePrimary myeloproliferative disordersElevated platelet countSymptoms of thrombosisAspirin therapyRecurrent thrombosisThrombotic complicationsAspirin treatmentArterial thrombosisDVT patientsThrombotic riskTransient thrombocytosisThrombosis riskDeep veinsSecondary thrombocytosisAbsolute countsMyeloproliferative disordersThrombosis
1997
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. PMID: 9308555, DOI: 10.1016/s0190-9622(97)70141-5.Peer-Reviewed Original ResearchConceptsVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsHypercoagulable stateLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersLow APC ratioLymphocyte and monocyte subset changes during cardiopulmonary bypass: Effects of aging and gender
Rinder C, Mathew J, Rinder H, Tracey J, Davis E, Smith B. Lymphocyte and monocyte subset changes during cardiopulmonary bypass: Effects of aging and gender. Translational Research 1997, 129: 592-602. PMID: 9178725, DOI: 10.1016/s0022-2143(97)90193-1.Peer-Reviewed Original ResearchConceptsCardiopulmonary bypassOlder patientsT cellsLower lymphocyte numbersPercentage of CD8Total lymphocyte countCardiac surgery patientsPostoperative day 1Age of patientsMononuclear cell subsetsNatural killer cellsExpression of CD11bPatterns of lymphocytesYears of ageEvidence of activationHLADR expressionInfectious complicationsLymphocyte subsetsElderly patientsLymphocyte countSurgery patientsYounger patientsCardiac surgeryLymphocyte numbersKiller cellsAcquired von Willebrand's disease: A concise review
Rinder M, Richard R, Rinder H. Acquired von Willebrand's disease: A concise review. American Journal Of Hematology 1997, 54: 139-145. PMID: 9034288, DOI: 10.1002/(sici)1096-8652(199702)54:2<139::aid-ajh7>3.0.co;2-y.Peer-Reviewed Original ResearchConceptsVon Willebrand factorHigh molecular weight multimersMonoclonal gammopathyAcquired von Willebrand diseaseEmergent cardiac surgeryUnderlying lymphoproliferative disorderLower functional levelUnderlying lymphoproliferative diseaseVon Willebrand diseaseIntravenous immunoglobulinCardiac surgeryLymphoproliferative disordersFactor inhibitorsAutoimmune diseasesLymphoproliferative diseaseUnderlying disorderEffective therapyBleeding diathesisIllustrative case historiesAvWDTherapeutic strategiesAntigenic levelsWillebrand diseaseReticuloendothelial systemTumor cells